Project Presentation

1

• Project Presentation

2
Content

• Aims
• Approach
• Problem statement expected breakthroughs
• Envisaged radical innovations
• Scientific technological objectives
• The Meddelcoat consortium
• Project structure co-operation
• Project work plan
• Project milestones
• Expected impact
• Administrative information contact

3
Aims of the MEDDELCOAT project
To develop the next generations of
multifunctional bioactive biocompatible coatings
with biofilm inhibition and optimal implant
fixation, eliminating the currently experienced
need for implant revisions due to implant
loosening and infections.
4
Approach of the MEDDELCOAT project
Combinatorial approach

• Design and engineer the structure of the implant
  surface to optimise implant fixation by
  osteointegration,
• Promote osteointegration by the application of a
  bioactive top coating,
• Incorporate a biofilm formation inhibiting
  function into the coating.

5
Problem statement expected breakthroughs
         
6
Problem statement expected breakthroughs
         
7
Envisaged radical innovations and major
breakthroughs

• Development of new substrate and coating
  materials with enhanced biocompatibility.
• Development of radically new or improvement of
  existing coating techniques for the processing of
  bioactive and biocompatible coatings with a
  graded interface (adhesion strength) and tailored
  porosity (bone in-growth).
• In-depth understanding of the implant
  substrate/coating/bone interfacial structure, the
  design, engineering and control for optimal
  implant fixation.
• Novel knowledge on interactions between new
  coating materials and bacteria and effective
  biofilm avoidance/elimination routes
• Evaluation of new biofilm inhibiting substances
• A formulation for the incorporation of
  anti-infective substances into the coating

8
Scientific technological objectives
9
Scientific technological objectives
10
Scientific technological objectives
11
MEDDELCOAT consortium
LEMI
12
Project structure partner co-operation
Selection of implants
(LIMA, Helipro)
Selection of implants (WP1)
(LIMA, Heli Pro)
RTD-activities (WP1-WP5) all
Innovation-related activities (WP6) all
Demonstration activities (WP8) all
LIMA, Helipro,
LIMA, HeliPro, AALTO
Substrates powders (WP1)
Substrates powders
KUL
KUL-MTM, ALHENIA, UoB
ALHENIA, AMES,
Alhenia, AMES,
Coating and sintering technology
Coating and sintering technology (WP2)
KUL
-
MTM, UoB, IJS
KUL-MTM, UoB, IJS
IMMG, KUL
-
MTM,
IMMG, KUL
-
MTM,
Characterisation and evaluation
Characterisation and evaluation (WP2)
UoB, IJS
UoB, IJS
Training activities (WP7) all partners
Coating design Engineering (all partners)
Training activities (all partners)
LIMA, AALTO,
Coating design Engineering (WP2) all partners
Modelling
LIMA, HUT, KUL
-
MTM, UoB
Modelling and finite element analysis (WP2)
KUL-MTM, UoB
KUL-REGA, HEMOTEQ
Bacteria
-
material interaction
KUL
-
REGA, OctoPlus
Bacteria
-
material interaction (WP3)
LEMI, HeliPro, IJS, KUL-MTM
Biocompatibility testing
Biocompatibility testing (WP4)
LEMI, Helipro, IJS, KUL
-
MTM
Upscaling feasibility (WP5)
all partners
Dissemination and exploitation (all partners)
13
Project work plan overview
WP 3 Bacteria-coating interaction
Task 3.1 Bacteria-coating interaction
investigation Task 3.2 Selection and
incorporation of biofilm inhibitors Task 3.3
Evaluation of biofilm inhibiting coatings
WP 2 Coating of implants
Task 2.2 Coatings for implant fixation Task
2.3 Bioresorbable and bioactive coatings Task
2.4 Thermal treatments Task 2.5 Structural
characterisation of coating/substrate systems
Task 2.6 Mechanical characterisation of
coating/substrate systems Task 2.7 Modelling
and finite element analysis thermodynamic and
kinetic modelling
WP 1 Substrates bioactive powders
Task 1.1 Selection supply of substrates and
implants Task 1.2 Selection supply of
bioactive powders
Task 2.1 Coating engineering design
WP 4 Biocompatibility and activity testing
Task 4.1 Cell culture of powders and coated
implants Task 4.2 Bioactivity and
resorbability testing of coatings Task 4.3
In-vivo testing of bone bonding
WP 5 Upscaling feasibility WP 6 Innovation
related activities WP 7 Demonstration activities
WP 8 Training activities WP 9 Project management
14
Project milestones
15
Project milestones
16
Project milestones
17
Expected impact of the MEDDELCOAT project

• Community societal objectives
• The project aims at a drastic decrease of implant
  failures, concomitantly reducing the number of
  revisions, lowering the pain and suffer of the
  patients and decreasing the medical costs for
  patients and community.
• The implementation of highly reliable implants
  definitely improves the mobility and quality of
  live of those among us who need it because of
  age, illness or accident.
• SME-driven market ! Small and medium size
  companies together make up more than 80 of
  medical technology business entities. This
  industry contributes significantly to saving life
  and improving the quality of life of the citizens
  of Europe.
• SMEs are the main job creators of European
  industry. MEDDELCOAT will enhance the ability of
  the SMEs involved to improve their
  competitiveness, with an immediately positive
  effect in job creation.

18
Expected impact of the MEDDELCOAT project

• Contribution to policy developments
• The project addresses the integration of
  nanotechnologies, material science and advanced
  technologies to improve health and quality of
  life of European citizens and creating wealth
  through novel knowledge-based and sustainable
  products (biomaterials) and processes (coatings).
  
• The project will contribute to a dynamic and
  competitive knowledge-based economy (Lisbon
  objective), sustainable development (Göteborg
  objective), and serves the needs of a traditional
  SME-intensive industrial sector.
• The project contributes to the ERA by focussing
  on nanotechnologies, intelligent materials and
  new production processes sustainable
  development genomics and biotechnology for
  health and citizens and governance in the
  European knowledge-based society (4 of the 7
  research priorities for Europe) and especially
  enhances the participation of SMEs in ERA.

19
Expected impact of the MEDDELCOAT project

• Biomedical implants are knowledge-based products
  with high added value. At present, about 60 of
  the implant market in Europe is controlled by
  non-EU companies. The development of a
  technology, as envisaged in the IP-SME project,
  would give competitive advantage to European SMEs
  which is of high interest not only to conserve
  employment, but also to create new jobs in
  Europe.
• The proposed research is of strategic importance
  to the EU in view of the massive impact on market
  share which would result from the development of
  the envisaged biomaterials with multifunctional
  bioresorbable biocompatible coatings with biofilm
  inhibition and optimal implant fixation.

20
Expected impact of the MEDDELCOAT project

• Gender issues
• The goal within this project is to reach a
  minimum of 25 of female researchers at the
  recruitment stage and encourage greater
  participation at senior level, which is
  significantly higher than the European average of
  15 for industrial research.
• Contribution to standards
• The activities related to the bacteria-material
  interaction investigation, the development and
  evaluation of coating integrated biofilm
  inhibitors, and biocompatibility testing will
  result in an active participation in European and
  international standardisation committees.

21
Expected impact of the MEDDELCOAT project

• Economic impact
• The 80B medical device industry continues to
  grow at 9 per year, driven by the aging global
  population and medical advances.
• Less than 5 of the medical device market now
  utilizes surface modification technology of any
  kind. As the demand for better, more advanced
  biomaterials accelerates in step with scientific
  breakthroughs, the market for surface
  modification of existing medical devices is
  expected to grow at approximately 80-90 per year
  for the next 5 years, as the market adopts
  "intelligent" coatings.
• Early adopters will use the coatings to either
  improve device biocompatibility or reduce
  infection later generations of coatings could
  conceivably employ a nearly infinite array of
  therapeutic agents. We anticipate that
  "intelligent" coatings for medical devices and
  biologic implants will become the standard of
  care.

22
Administrative information

• Project
• Type IP-SME
• Contract no. NMP3-CT-2006-02651
• www.meddelcoat.eu
• Project duration 01/10/2006 31/3/2011
• No. of person-months 674
• Budget
• Total project budget 4706 k
• EC funding 3300 k
• Project co-ordination K.U.Leuven RD (Leuven,
  Belgium)

23
Contact

• For further information
• Visit www.meddelcoat.eu
• Project coordinator

Prof. Dr. ir. Jef VleugelsKatholieke
Universiteit LeuvenDepartement of Metallurgy and
Materials Engineering (MTM)Kasteelpark Arenberg
44, B-3001 Heverlee (Belgium)phone
32-16-321244, fax [phone] E-mail
Jozef.vleugels_at_mtm.kuleuven.be